Recombinant antibodies for immunotherapy

著者

    • Little, Melvyn

書誌事項

Recombinant antibodies for immunotherapy

edited by Melvyn Little

Cambridge University Press, 2009

  • : hbk

大学図書館所蔵 件 / 全1件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.

目次

  • Part I. Introduction: 1. Past, present and future of recombinant antibodies G. Winter
  • Part II. Generation and Screening of Antibody Libraries: 2. Antibody libraries from naive V gene sources G. Beste and D. Lowe
  • 3. Antibodies from IgM libraries V. Molkenthin and S. Knackmuss
  • Part III. Transgenic Human Antibody Repertoires: 4. The generation and screening of synthetic antibody libraries I. Klagge
  • 5. Therapeutic antibodies from xenoMouse transgenic mice A. Jakobovits
  • 6. Transgenic chimeric antibodies A. Murphy
  • Part IV. Humanised Antibodies: 7. Humanization of recombinant antibodies J. Saldanha
  • 8. Immunogenicity assessment of antibody therapeutics P. Stas, J. Pletinckx, Y. Gansemans, and I. Lasters
  • 9. In vitro screening for antibody immunogenicity F. Carr and M. Baker
  • Part V. Antibody Effector Function: 10. Mechanisms of tumour cell killing by therapeutic antibodies R. Stewart and C. Webster
  • 11. Optimization of Fc domains to enhance antibody therapeutics G. Lazar and A. Chamberlain
  • 12. Glycoengineered therapeutic antibodies P. Brunker, P. Sondermann, and P. Umana
  • Part VI. Arming Antibodies: 13. Monoclonal antibodies for the delivery of cytotoxic drugs D. King
  • 14. Immunotherapy with radioimmune conjugates C. Kousparou and A. Epenetos
  • 15. Immunotherapeutic antibody fusion proteins N. Courtenay-Luck and D. Jones
  • Part VII. Antibody Fragments: 16. Alternative antibody formats F. Le Gall and M. Little
  • 17. Single domain antibodies S. Muyldermans
  • 18. Engineering of non-CDR loops in immunoglobulin domains F. Ruker and G. Wozniak-Knopp
  • Part VIII. Antigen Binding Repertoires of Non-Immunoglobulin Proteins: 19. Alternative antibody scaffolds A. Plueckthun
  • Part IX. Prolongation of Serum Half Life: 20. Polymer fusions to increase antibody half lives: PEGylation and other modifications S. Heywood and D. Humphreys
  • 21. Extending antibody half-lives with albumin J. Andersen and I. Sandlie
  • Part X. Current Therapeutic Antibodies and Novel Developments: 22. A stem cell-based platform for the discovery and development of anti-tumor therapeutic antibodies to novel targets J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, and D. Loo
  • 23. Antibody directed enzyme prodrug therapy (ADEPT) H. Lowe, S. Sharma, and K. Bagshawe
  • 24. Immune privilege and tolerance - therapeutic antibody approaches D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, and M. Rosenzweig
  • Part XI. Market Overview and Outlook: 25. Antibody therapeutics: business achievements and business outlook C. Bourrilly.

「Nielsen BookData」 より

詳細情報

ページトップへ